Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market PotentialSAN JOSE, Calif., July 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025, cove ...